Calculate PSA density from total PSA and prostate volume, assess prostate cancer risk, compute free/total PSA ratio, and compare with age-specific and BPH-expected PSA levels.
PSA density (PSAD) refines prostate cancer risk assessment by normalizing the total PSA level to prostate size, since benign prostatic hyperplasia (BPH) alone can elevate PSA through increased glandular tissue mass. A large prostate naturally produces more PSA, so a total PSA of 6 ng/mL in a man with a 60 cc prostate (PSAD 0.10) carries much less cancer significance than the same PSA in a man with a 25 cc prostate (PSAD 0.24).
This calculator computes PSAD from total PSA and prostate volume (measured by TRUS, MRI, or calculated from ultrasound dimensions using the prolate ellipsoid formula), applies established risk thresholds to guide biopsy decisions, and incorporates additional PSA refinements including the free/total PSA ratio and age-specific reference ranges. It also estimates the PSA contribution expected from BPH alone (~0.066 ng/mL per cc of prostate tissue), allowing clinicians to identify "PSA excess" above what benign enlargement would explain.
PSAD has become increasingly important in the prostate MRI era: the PI-RADS assessment framework specifically incorporates PSAD thresholds for PI-RADS 3 (equivocal) lesions, where a PSAD >0.15 favors targeted biopsy while a PSAD <0.10 may support active surveillance or continued monitoring.
This calculator normalizes PSA to prostate size for more accurate cancer risk assessment, computes BPH-expected PSA to identify suspicious excess, includes the free/total PSA ratio, and provides age-specific reference ranges — all essential tools for informed prostate cancer screening decisions. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain. Use this clarification to avoid ambiguous interpretation.
PSAD = Total PSA (ng/mL) / Prostate Volume (cc). Prostate Volume (ellipsoid) = Length × Width × Height × 0.523. BPH-expected PSA ≈ Volume × 0.066 ng/mL/cc. Free/Total PSA ratio = (Free PSA / Total PSA) × 100.
Result: PSAD = 0.150 ng/mL/cc, Suspicious — consider biopsy, BPH-expected PSA = 2.6 ng/mL, PSA excess +3.4
With PSA 6.0 and prostate volume 40 cc, PSAD = 0.15. This is at the threshold where biopsy is generally recommended. BPH alone would explain ~2.6 ng/mL of PSA, leaving 3.4 ng/mL unexplained by benign enlargement.
Use consistent units, verify assumptions, and document conversion standards for repeatable outcomes.
Most mistakes come from mixed standards, rounding too early, or misread labels. Recheck final values before use. ## Practical Notes
Use this for repeatability, keep assumptions explicit. ## Practical Notes
Track units and conversion paths before applying the result. ## Practical Notes
Use this note as a quick practical validation checkpoint. ## Practical Notes
Keep this guidance aligned to expected inputs. ## Practical Notes
Use as a sanity check against edge-case outputs. ## Practical Notes
Capture likely mistakes before publishing this value. ## Practical Notes
Document expected ranges when sharing results.
A PSAD >0.15 ng/mL/cc is generally considered suspicious and often triggers biopsy referral, especially in the PSA 4–10 "grey zone." PSAD >0.20 is associated with higher risk of clinically significant prostate cancer.
Prostate volume is most accurately measured by MRI. Transrectal ultrasound (TRUS) is the traditional method. The prolate ellipsoid formula (L × W × H × 0.523) calculates volume from three dimensions.
Free PSA is not bound to proteins. Cancer tends to produce more bound PSA, lowering the free/total ratio. A ratio <15% suggests higher cancer risk (~28%), while >25% suggests lower risk (~8%). It is most useful when total PSA is in the 4–10 ng/mL grey zone.
No — PSAD supplements total PSA. It is most useful in the PSA 4–10 ng/mL grey zone, where total PSA alone has poor specificity. PSAD helps distinguish cancer from BPH-driven PSA elevation.
In the PI-RADS framework, PSAD helps triage PI-RADS 3 (equivocal) lesions. PSAD >0.15 favors targeted biopsy; PSAD <0.10 supports watchful monitoring. PI-RADS 4–5 lesions warrant biopsy regardless of PSAD.
The prolate ellipsoid formula (L × W × H × π/6 ≈ 0.523) correlates well with planimetric MRI volumes for glands under ~80 cc. For very large or irregularly shaped prostates, MRI volumetry may be more accurate.